Journal of Alzheimers Disease & Parkinsonism
Open Access

Manikandan Samidurai

Biography

• Antibody design for the degradation of intracellular tau oligomers • Role of Protein misfolding and aggregation in Senescence Postdoctoral Research Associate, ISU. 2018- July 2022 • Found novel tyrosine kinase that involves in the NLRP3 inflammasome formation by enhancing ASC phosphorylation and aggregation in the microglia. • Discovered new α-Synuclein interacting receptor might be responsible for microglia dysfunction and neurodegeneration in the brain by using engineered mouse knockouts and over-expressing models. • Demonstrated that acute and chronic elimination of Microglia by small molecule improves neuronal survival and suppresses neuroinflammation in PD mice models. • Evaluated the pharmacokinetics, Therapeutic efficacy, and Blood brain barrier accessibility of small molecules that that inhibits microglial activation in Parkinson’s Disease, epilepsy neuroinflammation animal models. • Identified elevated levels of novel proinflammatory cytokine, modified circulating histones in human PD patient’s brain and serum samples and validated these proteins as a useful target in models of Parkinson’s disease. • Found exosome circulating histone-receptor interaction mechanism which involved in the activation of the M1 microglia in primary mouse microglia culture. • Found correlation between the upregulation of microglial potassium/calcium channels and inflammasome activation in PD and identified as a potential therapeutic target for PD. • Directly mentored graduate students by developing environmental toxicology-based projects, designing experiments, technical expertise, data analysis, and scientific communication. Ph. D Research Scholar / Biomedical Sciences (Neuroscience) 2015 – 2018 • Discovered a novel receptor pathway involved in the Alzheimer’s disease through molecular interaction studies and electrophysiological approach. • Investigated and tested novel specific receptor targeting small molecule as a therapeutic for Amyloid beta mediating neuroinflammation both in vitro, using primary cultures, and animal models. • Found novel signaling pathway involved in Amyloid Beta induced LTP inhibition in Alzheimer’s disease through using Electrophysiological approach. • Maintenance and breeding of two Alzheimer’s disease Transgenic animal models (Tg2576 & 5X FAD). • Jointly Characterized end evaluated the nano material to reduce the neuroinflammation in microglia. • Established and developed method for animal surgery (CSF collection )

Research Interest

3+ years of research experience in Neurodegenerative disorders research and In vivo/Invitro Pharmacological studies. • Expertise in preclinical study strategies, drug discovery execution and animal model development with various Toxicants misfolded and aggregated proteins related to neuroinflammation, Alzheimer’s and Parkinson’s disease. • Adept in AAV vector strategy development & execution for the generation of microglial specific gene knock down in mouse. Proficient in the gene target identification via biochemical and molecular methodologies. • Proficiency in pharmacokinetics, Therapeutic efficacy, Toxicological evaluation of small molecules. • Proficient in rodent surgeries such as Stereotaxic, telemetry implantation and behavioral testing, analysis. • Competent in primary neuronal, glial and IPSC cell culture experiments including gene knock out, gene overexpression and stable cell line generation. • Collaborated with multi-university group on generating and validating conditional knock out mouse model and developed successfully. • Led research group in equipment management and facilitated maintenance & training. Experienced practice in EH&S, IACUC regulations